특허 및 논문

Intellectual Property (cont.)

33 Kim, S. J., and Lee, S.-W. (2014) Selective expression of transgene using hypoxia-inducible trans-splicing group I intron ribozyme. Journal of Biotechnology 192: 22-27.
32 Kim, J., Jeong, S., Kertsburg, A., Soukup, G. A., and Lee, S.-W. (2014) Conditional and target-specific transgene induction through RNA replacement using an allosteric trans-splicing ribozyme. ACS Chemical Biology 9(11): 2491-2495.
31 Kim, Y.-H., Moon, J. Y., Kim, E.-O., Lee, S. J., Kang, S.H., Kim, S. K., Heo, K., Lee, Y., Kim, H., Kim, K. T., Kim, D., Song, M. S., Lee, S.-W., Lee, Y., Koh, S. S., and Kim, I.-H. (2014) Efficient targeting and tumor retardation effect of pancreatic ade
30 Lee, S.-W., and Jeong J. S. (2014) Use of tumor-targeting trans-splicing ribozyme for cancer treatment. Methods in Molecular Biology 1103: 83-95.
29 Won, Y.-S., and Lee, S.-W. (2012) Selective regression of cancer cells expressing a splicing variant of AIMP2 through targeted RNA replacement by trans-splicing ribozyme. Journal of Biotechnology 158: 44-49.
28 Won, Y.-S., and Lee, S.-W. (2012) Cancer-specific induction of adenoviral E1A expression by group I intron-based trans-splicing ribozyme. Journal of Microbiology and Biotechnology 22: 431-435.
27 Lee, C. H., Kim, J. H., Kim, H. W., Myung, H., and Lee, S.-W. (2012) Hepatitis C virus replication-specific inhibition of microRNA activity with self-cleavable allosteric ribozyme. Nucleic Acid Therapeutics 22: 17-29.
26 Ban, G., Jeong, J.-S., Kim, A., Kim, S. J., Han, S.-Y., Kim, I.-H., and Lee, S.-W. (2011) Selective and efficient retardation of cancers expressing cytoskeleton-associated protein 2 by targeted RNA replacement. International Journal of Cancer 129: 1018-10
25 Kwon, B.-S., Jeong, J. S., Won, Y. S., Lee, C. H., Yoon, K.-S., Jung, M. H., Kim, I.-H., and Lee, S.-W. (2011). Intracellular efficacy of tumor-targeting group I intron-based trans-splicing ribozyme. The Journal of Gene Medicine 13: 89-100.
24 Lee, S. J., Lee, S.-W., Jeong, J. S., and Kim, I. H. (2010). In vivo reprogramming of human telomerase reverse transcriptase (hTERT) by trans-splicing ribozyme to target tumor cells. Methods in Molecular Biology 629: 307-321.